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The coronary slow ﬂow phenomenon (CSFP) is a disease entity characterized by slow progression of angiographic contrast
in the coronary arteries in the absence of stenosis in the epicardial vessels. CSFP has a diverse presentation from mild chest
discomfort to ST-segment elevation myocardial infarction. It can also have severe morbidity and mortality implications and
can signiﬁcantly hamper the quality of life of those aﬀected. In this paper we present two patients with CSFP highlighting the
diverse spectrum of presentation. A concise review of the literature is also provided emphasizing the epidemiology, pathogenesis,
diagnostic parameters, treatment modalities, and clinical signiﬁcance of this phenomenon.
1. CasePresentations
1.1. Patient 1. The ﬁrst case involved a 43-year-old man with
a past medical history of hyperlipidemia and hypertension
who presented to the hospital with chest pain. The chest
pain was described as a pressure-like sensation in the
center of his chest, 8/10 in severity, and radiated down
his left arm. Upon presentation, vital signs were stable,
cardiac biomarkers were within normal limits, and the
electrocardiogram (EKG) showed no ST/T-waves changes.
Transthoracic echocardiogram showed normal left ventricle
function and no wall motion abnormalities. Of note, the
patient had a similar presentation and ER course two weeks
prior.
Due to the fact that the patient continued to have 8/10
chest pain during his hospital stay, coronary angiogram was
ultimately done. The angiogram showed normal coronary
arteries without evidence of coronary vasospasm or an
existing myocardial bridge. Slow ﬂow, however, was noted in
the left anterior descending artery (LAD). An intracoronary
adenosine challenge was done and showed normalization
of the TIMI (Thrombolysis in Myocardial Infarction) frame
count (Figure 1). The patient was given the diagnosis of
coronary slow ﬂow phenomenon and started on dipyri-
damole 50mg three times a day and discharged home.
On six-month followup, the patient reported that he had
been chest-pain-free. Shortly after his six-month followup,
the patient ran out of his medicine and again began to
experience chest pain. Once the patient was placed back on
his dipyridamole, he became chest-pain-free.
1.2. Patient 2. The second case involved a 70-year-old
gentleman with a past medical history of squamous cell
carcinoma of the base of tongue six years prior. The patient
presented with a single episode of chest pain at rest described
as pressure-like and associated with shortness of breath and
diaphoresis.AdmissionEKGrevealedT-waveinversioninthe
anterior leads and a prolonged QT interval (Figure 2). Car-
diac enzymes were also noted to be elevated (CKMB 8.3IU/l
and troponin I 1.14ng/mL). Transthoracic echocardiogram
showed normal leftventricularfunctionwith no wallmotion
abnormalities or left ventricular hypertrophy. A diagnosis
of non-ST-elevation myocardial infarction (NSTEMI) was
made, and the patient was started on the appropriate acute
coronary syndrome medications. Left heart catheterization
was done the following day and revealed normal coronary2 Cardiology Research and Practice
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Figure 1: Corrected TIMI frame counting method of left anterior descending artery (LAD), Gibson’s method with correction factor of 1.7
for LAD. Image on left (arrow) is when ostium is ﬁrst opaciﬁed by contrast. Image on the right (arrow) is when the distal LAD is opaciﬁed
by contrast. Patient’s preadenosine TIMI frame count was 42 and postadenosine TIMI frame count was 14.
Figure 2: Electrocardiogram showing T-wave inversion in leads
V1–V4. QT interval is also prolonged (QT-534MS and QTc = 510
MS).
arteries with slow ﬂow noted in LAD. An intracoronary
adenosine challenge was done that showed normalization of
the TIMI frame count (Figure 3). The patient was given the
diagnosis of coronary slow ﬂow and started on amlodipine
2.5mg daily. On 6-month followup, the patient reports that
he has been chest-pain-free.
2.Introduction
CSFP was ﬁrst described by Tambe et al. in 1972, and is
deﬁned as delayed opaciﬁcation of coronary vessels during
angiography without any evident obstructive disease [1].
Quantitatively, it is measured as increased Thrombolysis
in Myocardial Infarction (TIMI) frame count. TIMI frame
count, introduced by Gibson, is a reproducible index of
coronary ﬂow and represents the number of cine frames
required for contrast to reach a prespeciﬁed distal coronary
artery landmark. TIMI frame count is further corrected in
the left anterior descending artery (LAD) by normalizing for
the LAD length. The corrected TIMI frame count (CTFC)
divides the absolute TIMI frame count in the LAD by 1.7.
CSFP is deﬁned as CTFC > 2 standard deviations from
normal published range (21 ± 3) [2].
3. Presentation
The presentation of this phenomenon is extremely diverse
ranging from stable or unstable angina, non-ST-elevation
myocardial infarction (NSTEMI), ST-elevation myocardial
infarction (STEMI), nonsustained ventricular tachycardia
(NSVT), and even vague chest discomfort. Yilmaz et al.
found in their study that patients with CSFP had higher total
cholesterol level (including higher low-density lipoprotein
levels), higher body mass index, and a higher prevalence of
metabolic syndrome [3]. Azzarelli et al. showed in a case
series that patients with CSFP often present with recurrent
chest pain [4]. New onset intermittent left bundle branch
block (LBBB) has also been reported in association with
CSFP in a patient presenting with acute coronary syndrome
[5].
4. Incidence
The overall incidence of CSFP is 1% among patients who
undergo coronary angiography, especially those presenting
with acute coronary syndrome [6]. In TIMI-IIIA study, the
incidence of CSFP was 4% among patients who presented
withunstableanginaandhadnoneorinsigniﬁcantepicardial
coronary artery disease [7].
5. Pathogenesis
The pathogenesis of CSFP is still not well understood. There
are some typical histopathological features associated with
CSFP based on which reduction of luminal diameter and
functional obstruction are believed to be the key events in its
pathogenesis. Mosseri et al. demonstrated medial hypertro-
phy, myointimal proliferation, and endothelial degeneration
along with changes of myoﬁbrillar degenerative foci withCardiology Research and Practice 3
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Figure 3: Corrected TIMI frame counting method of left anterior descending artery (LAD), Gibson’s method with correction factor of 1.7
for LAD. Image on left (arrow) is when ostium is ﬁrst opaciﬁed by contrast. Image on the right (arrow) is when the distal LAD is opaciﬁed
by contrast. Patient’s preadenosine TIMI frame count was 65 and postadenosine TIMI frame count was 16.
lipofuscindepositsatelectronmicroscopiclevel[8].Luminal
narrowing was attributed to endothelial swelling and degen-
eration. Mangieri et al. substantiated these ﬁndings in CSFP
patients by showing small vessel thickening with associated
luminal narrowing, dilated interstitial spaces ﬁlled with
granular ﬁbrillar material, decreased intracellular glycogen,
distorted mitochondrial cristae, and patchy myoﬁbrillar
disarray at electron microscopic level [9]. Based on this, it
was suggested that ﬁbromuscular hyperplasia and medial
hypertrophy with consequent decrease in luminal diameter
lead to functional obstruction and CSFP.
The occurrence of CSFP is also believed to be strongly
associated with elevated homocysteine levels which cause
signiﬁcant injury and consequent endothelial impairment
[10]. Endothelial damage secondary to decreased nitric
oxide levels, with elevated levels of nitric oxide synthase
inhibitor and asymmetric dimethyl arginine (ADMA) are
also considered as chief contributory factors [11, 12]. The
basic underlying event is endothelial injury which leads to
functional obstruction and disease manifestation.
Aortic pulse pressure and pulsatility index was found to
be signiﬁcantly elevated in patients with CSFP. It is believed
that this could possibly be caused by endothelial dysfunction
in CSFP. Increased aortic stiﬀness in CSFP was shown by
Tanriverdi et al. in a study of 154 patients which included 81
patients with angiographically proven CSFP and 73 patients
with normal coronary ﬂow [13].
Impaired coronary ﬂow reserve is another important
feature in CSFP which is related to increased resting coro-
nary microvascular tone. With increased myocardial oxygen
demand, the inability to maximize coronary ﬂow can reﬂect
as persistent and recurrent chest pain in CSFP. In a study
by Erdogan et al. which included 20 patients with CSFP and
15 controls, coronary ﬂow reserve was signiﬁcantly reduced
in the CSFP group [18]. This was also shown by Mangieri
et al. in a study of twenty-eight patients with CSFP in
which 14 patients had coronary slow ﬂow in one vessel and
14 had coronary slow ﬂow in three vessels. After dipyri-
damole infusion, coronary angiography was done and single
Table 1: Characteristic disease associations of CSFP.
Salient associations of CSFP
Chronically elevated resting microvascular endothelial tone [14]
High incidence of metabolic syndrome [15]
Normal large artery stiﬀness between acute episodes [16]
Prolonged P-wave duration
Increased P-wave dispersion [17]
Increased aortic pulse pressure, fractional pulse pressure, and
pulsatility index (parameters of aortic elasticity indicating
increased aortic stiﬀness)
Impaired coronary ﬂow reserve
photon emission computed tomography (SPECT) scan was
performed. Interestingly, TIMI frame count decreased after
dipyridamole infusion in both groups while SPECT score
increased in the ﬁrst group and was reduced in the second
group [19]. This suggests that myocardial perfusion in more
extensive CSFP is signiﬁcantly impaired and reﬂects the poor
coronaryﬂowreserveinthesepatients.Alistofcharacteristic
disease associations of CSFP is outlined in Table 1.
6. Treatment
The treatment for CSFP is still a matter of debate and a
number of drugs have shown variable beneﬁts. Simvastatin
has shown to improve myocardial perfusion in patients with
CSFP [20]. The pleiotropic eﬀect, direct endothelial func-
tion eﬀect, and the antithrombotic and anti-inﬂammatory
actions of statins appear to be responsible for this improved
perfusion [21]. In a study by Fan et al. which included 91
patients with CSFP, signiﬁcant improvement in coronary
ﬂow reserve was shown after treatment with atorvastatin
20mg daily for eight weeks [22]. This study highlights the
importance of statin therapy in treatment of CSFP.
Nebivolol has also shown to be eﬀective at improving
endothelial function in patients with CSFP. It controls chest4 Cardiology Research and Practice
Table 2: Comparison of coronary slow ﬂow phenomenon (CSFP) versus syndrome X.
CSFP Syndrome X
Males [29] Postmenopausal females [29]
Current smokers [29] Current or past smokers [29]
Unstable angina [30] Stress-related angina [30]
Elevated resting microvascular tone [31] Normal resting microvascular tone [31]
Normal vasodilator response to papaverine, adenosine, and during exercise [31] Typically absent [31]
Greater rate of life threatening cardiac arrhythmias and sudden cardiac death [27] Lower incidence as compared to CSFP [27]
pain, decreases C reactive protein (CRP), and signiﬁcantly
improves coronary ﬂow [23].
Dipyridamole, which has a vasodilator eﬀect on the
coronary microvasculature, is being used as treatment for
CSFP as well. In a study where 25 patients with CSFP
were administered dipyridamole 75mg three times a day
for one month, coronary ﬂow returned to normal in 70
out of 75 vessels. Typical angina complaints resolved in 17
patients (68%), and decreased in frequency in the remaining
8 patients (32%) [24]. Dipyridamole abolishes functional
obstruction in coronary arteries with diameters less than 200
micrometers and is considered far superior in treating CSFP
as compared to nitroglycerine [24].
There is no substantial data regarding the use of con-
ventional calcium L-channel blockers such as amlodipine
in patients with CSFP. It was used in the second case
as described above because calcium channel blockers are
macro- and microvascular vasodilators used for slow ﬂow
during percutaneous coronary intervention (PCI). In one
study regarding clinical and angiographic beneﬁts of the
calcium T-channel blocker mibefradil in CSFP patients,
results showed reduction of total angina frequency by 56%,
prolonged angina episodes > 20 minutes by 74%, and sub-
lingual nitroglycerine consumption by 59% over a 12-month
period. Angiographically, 13 out of 18 vessels showing TIMI-
2 ﬂow had abolition of the slow ﬂow [25]. Currently, its use
is limited due to occurrence of extensive drug interactions by
inhibition of the cytochrome P450 3A4 pathway [26].
7. Syndrome X
An important diﬀerential to be considered in the diagnosis
of CSFP is coronary syndrome X. Over the last few years, a
number of important distinguishing features between these
two seemingly similar entities have been identiﬁed (Table 2).
In a study of 49 patients, Atak et al. documented increased
QTcdispersioninpatientswithCSFP,whichgreatlyincreases
the predisposition of sudden cardiac death due to malignant
ventricular arrhythmias [27]. CSFP has also been termed
as syndrome Y because of its interesting occurrence in
syndrome X patients, after administration of neuropeptide
Y[ 28].
8.Prognosis
The major long-term problem in CSFP patients is persistent
and recurrent chest pain. One-third of these patients require
readmission for an acute exacerbation [32]. In a study of
88 patients with angina and normal coronary arteries over a
followupperiodof6–11years,chestpaindiminishedin47%,
and symptoms were unchanged in 24% or even worse in
29% of patients. However, 81% of patients with documented
CSFP at coronary angiography reported chest pain to be
similar or even worse than the initial episode [33].
Resting EKG abnormalities and positive exercise stress
tests are more frequent in patients with CSFP. In one study
of 53 patients with angina and angiographically normal
epicardial coronary arteries and 40% having documented
CSFP, 57% of patients had worsening or persistence of
symptoms, and nonsigniﬁcant resting EKG abnormalities
were seen in 27% while exercise-induced functional and
perfusion abnormalities occurred in 69% of patients [34].
Patients with CSFP have a favorable long-term prognosis
as reported by Lichtlen et al. in a prospective study of 176
patients with angina and normal coronary arteries. The
median followup time period was 12.4 years. The rate of fatal
myocardial infarction was found to be 0.05% per year, risk
of death from coronary artery disease was 0.09% per year,
and the rate of nonfatal myocardial infarction occurrence
was 0.18% per year [35].
9. Conclusion
The major implications of this disease entity are reﬂected
in the hampering of day-to-day life of CSFP patients with
persistent chest pain and multiple hospital admissions. This
is highlighted particularly well in the two cases presented
here. There is a need for further extensive studies regarding
the detailed pathogenesis and newer eﬀective treatment
modalities for this unique phenomenon with the potential
to ameliorate the poor quality of life of patients with CSFP.
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